By Sasha Jones, New York City
Publication Date: 2026-01-12 16:29:00
Nvidia and Eli Lilly and Co. are partnering to build an artificial intelligence-powered laboratory in Silicon Valley, a push to deepen AI technology’s influence in biotechnology and the pharmaceutical industry.
Eli Lilly and Co. opened its Tech and Innovation Center in Hyderabad, India, in 2025.
The two companies plan to invest up to $1B in infrastructure and talent over the next five years. Construction is expected to begin in South San Francisco early this year, according to a Monday announcement.
The partnership aims to generate large-scale data and build AI models that may accelerate medicine development, using Nvidia BioNeMo, a platform for biology and drug discovery.
“AI is transforming every industry, and its most profound impact will be in life sciences,” Nvidia founder and CEO Jensen Huang said in a statement. “NVIDIA and Lilly are bringing together the best of our industries to invent a new blueprint for drug discovery — one where scientists can explore vast biological and chemical spaces in silico before a single molecule is made.”
It isn’t clear where the…
